IRIS
MONTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.108
AS - Asia 1.373
EU - Europa 1.008
SA - Sud America 189
Continente sconosciuto - Info sul continente non disponibili 91
AF - Africa 70
OC - Oceania 2
Totale 4.841
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.046
CN - Cina 471
SG - Singapore 412
IE - Irlanda 318
HK - Hong Kong 178
RU - Federazione Russa 152
BR - Brasile 146
DE - Germania 139
VN - Vietnam 123
IT - Italia 95
FI - Finlandia 75
FR - Francia 53
GB - Regno Unito 40
ZA - Sudafrica 39
IN - India 35
CA - Canada 29
BD - Bangladesh 26
SE - Svezia 26
ES - Italia 22
AT - Austria 21
MX - Messico 18
AR - Argentina 17
ID - Indonesia 14
IQ - Iraq 13
PK - Pakistan 13
NL - Olanda 12
TR - Turchia 12
JP - Giappone 10
PL - Polonia 10
SA - Arabia Saudita 10
BE - Belgio 9
EC - Ecuador 8
LT - Lituania 8
MY - Malesia 8
SN - Senegal 8
CZ - Repubblica Ceca 7
EG - Egitto 7
UA - Ucraina 7
CO - Colombia 6
JO - Giordania 6
UZ - Uzbekistan 5
NP - Nepal 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
BH - Bahrain 3
CR - Costa Rica 3
DK - Danimarca 3
ET - Etiopia 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PE - Perù 3
PY - Paraguay 3
VE - Venezuela 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GD - Grenada 2
JM - Giamaica 2
LB - Libano 2
LY - Libia 2
MA - Marocco 2
OM - Oman 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
BY - Bielorussia 1
CH - Svizzera 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
MV - Maldive 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SO - Somalia 1
SV - El Salvador 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
YT - Mayotte 1
Totale 4.751
Salva come PNG Salva come JPEG
Città #
Dublin 314
Chandler 309
Singapore 234
San Jose 224
Ashburn 198
Dallas 178
Hong Kong 175
Beijing 127
New York 65
Los Angeles 60
Boardman 57
Helsinki 56
Council Bluffs 54
Munich 53
Princeton 51
Lauterbourg 49
Ho Chi Minh City 47
Lawrence 46
Shanghai 42
Nanjing 34
Johannesburg 33
Hanoi 31
Jacksonville 28
Medford 28
Wilmington 28
Chicago 26
Moscow 25
Buffalo 19
Pavia 19
Redondo Beach 19
Changsha 18
Nanchang 18
Vienna 18
Santa Clara 17
Seattle 15
São Paulo 15
Frankfurt am Main 14
Orem 14
Brooklyn 12
Fairfield 12
Falkenstein 12
Milan 12
Hangzhou 11
Hebei 11
Montreal 11
Toronto 10
Turku 10
Brussels 9
Columbus 9
Jiaxing 9
London 9
Warsaw 9
Washington 9
Chennai 8
Da Nang 8
Dakar 8
Manchester 8
Phoenix 8
Shenyang 8
Tokyo 8
Ankara 7
Atlanta 7
Denver 7
San Francisco 7
Amman 6
Amsterdam 6
Tianjin 6
Belo Horizonte 5
Boston 5
Brno 5
Cagliari 5
Jakarta 5
Norwalk 5
Nuremberg 5
Rio de Janeiro 5
Tashkent 5
The Dalles 5
Albuquerque 4
Berlin 4
Guangzhou 4
Houston 4
Jeddah 4
Kuala Lumpur 4
Mexico City 4
Philadelphia 4
Poplar 4
Redwood City 4
Stockholm 4
Ann Arbor 3
Anápolis 3
Cape Town 3
Cleveland 3
Colombo 3
Genoa 3
Karachi 3
Manama 3
Memphis 3
Miami 3
Milwaukee 3
Mumbai 3
Totale 3.145
Salva come PNG Salva come JPEG
Nome #
The role of Trimethoprim/sulfametoxazole in reducing relapses and risk of infec-tions in ANCA-associated vasculitis: a meta-analysis 177
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 134
Is it really infective endocarditis? Distinguishing systemic vasculitis from its mimics 134
20 years of experience with tumour necrosis factor inhibitors: what have we learned? 128
Cytomegalovirus colitis unmasking human immunodeficiency virus infection as a cause of IgA vasculitis 122
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management 116
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 116
Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse 113
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 112
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 110
Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis 107
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 106
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 101
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 100
Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis 99
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature 98
Chronic pain: The burden of disease and treatment innovations 97
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies 97
Novel Therapies for ANCA-associated Vasculitis 97
Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis 95
Lumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case 95
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners 95
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs 92
Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature 91
Novel Diagnostic and Prognostic Approaches to Systemic Vasculitides 91
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors 89
Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment 88
Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study 86
Clinical spectrum of anti-Jo-1-associated disease 85
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis 85
Retention rate of IL-1 inhibitors in Schnitzler's syndrome 83
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak 81
Early development of new cardiovascular risk factors in the systemic vasculitides 78
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al 77
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: Are all biological disease-modifying antirheumatic drugs alike? Response to: Â € Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al 72
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 71
Switching from intravenous to subcutaneous formulation of abatacept: Different results in a series of 21 patients 71
Remission and Low-Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual 69
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: Ͽ Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and SLE, hydroxychloroquine and no SLE patients with COVID-19: A comment' by Joob and Wiwanitkit 68
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 66
Development and implementation of the AIDA International Registry for patients with Behçet’s disease 65
Pneumocephalus due to granulomatosis with polyangiitis 64
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al 62
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 61
Striking abdominal aortic stenosis revealing Takayasu's arteritis 59
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia' by Guilpain et al 56
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 55
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 53
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler et al 53
Pneumocephalus due to granulomatosis with polyangiitis 52
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 50
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 49
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients 48
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 48
Prevalence of COVID-19 among patients with rheumatic diseases: The need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al 48
Non-steroidal anti-inflammatory treatment during covid-19: Friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al 41
Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort 39
Updates on the diagnosis and monitoring of giant cell arteritis 28
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease 18
Totale 4.841
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.550
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.550
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022199 0 1 13 2 4 14 1 11 9 6 27 111
2022/2023859 87 82 6 68 73 80 3 42 375 9 18 16
2023/2024396 63 75 18 16 30 83 25 32 3 20 15 16
2024/2025897 36 63 10 29 18 59 43 51 219 37 91 241
2025/20262.042 178 148 234 190 270 95 340 119 204 133 54 77
2026/2027146 89 57 0 0 0 0 0 0 0 0 0 0
Totale 4.841